Global Bi-Specific Antibodies Therapy Market By Clinical Trials (Preclinical, Phase I, Phase II, Phase III, Commercial); By Drug (Blinatumomab, Emicizumab, Amivantamab-vmjw, Mosunetuzumab, Others); By Route of Administration (Intravenous, Subcutaneous); By Application (Cancer, Autoimmune Diseases, Infectious Diseases, Neurologic, Cardiovascular Diseases, Others); By End-User (Hospitals, Specialty clinics, Research Institutions, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Report ID :AMI-1202 | Category : Healthcare | Published Date : July, 2022 | Pages : 402 | Format :PDF

Request For Customization